Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


The Genetics Company enters a distribution agreement with Funakoshi Co., Ltd. of Japan.


The Genetics Company, Inc. a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer’s disease and cancer announces that it has entered a distribution agreement with Funakoshi Co., Ltd., a prime Japanese distributor of life science research reagents and instruments. Within the scope of this agreement The Genetics Company will supply Funakoshi Co., Ltd. with its innovative Alzheimer’s disease diagnostic products and research tools for exclusive distribution within Japan.

The Genetics Company's Alzheimer’s disease diagnostic products and research tools enable the highly specific and selective detection of variants of human beta-Amyloid, a key protein associated with the pathogenesis of Alzheimer’s disease. The Company's products include a very sensitive and reliable ELISA based kit for the quantification of beta-Amyloid 40 and 42 peptides in cerebrospinal fluid of patients (CSF ELISA), a method which already has been and continues to be validated in clinical trials and which emerges as an indispensable part of the Alzheimer’s disease diagnosis process in patients. A high sensitivity research version of these test kits, especially designed for the detection of beta-Amyloid 40 and 42 peptides in cell supernatants, brain lysates and other matrices, is also available for use in preclinical research. These ELISA test kits are complemented by superior quality antibodies for the detection of beta-Amyloid 40 and 42. These products will now become available on the Japanese market for the first time through exclusive distribution by Funakoshi Co., Ltd., who are a major Japanese distributor of innovative diagnostic products and reagents and who have recently been awarded the Gold Medal for their extraordinarily well-designed website (Bio Japan Best Web Gold Medal Award).

Dr. Ryoya Funakoshi, President & CEO of Funakoshi Co., Ltd. was quoted as saying “We are delighted with this distribution agreement, The Genetics Company’s outstanding ELISAs and antibodies perfectly complement our range of top quality products and will enable us to meet the high demand for beta-Amyloid-targeted Alzheimer's diagnostic and research tools in Japan”. Whereas, Dr. Harald Eistetter, CEO of The Genetics Company, adding the following comments “We appreciate that Funakoshi Co., Ltd. operates as our distributor for our Alzheimer’s disease diagnostics and research tools in Japan. Funakoshi have an excellent reputation in Japan and we look forward to a long and fruitful cooperation”.

About Funakoshi Co., Ltd.
Funakoshi Co., Ltd. is leading Japanese distributor of life science research reagents and instruments covering a wide range of areas including Molecular Biology, Immunology and Biochemistry. The Company offers in excess of 110,000 products from over 400 worldwide suppliers to a large range of research institutes and universities as well as biotechnological, agricultural, food and pharmaceutical companies. Customers include Japanese Governmental Laboratories such as the National Center of Neurology and Psychiatry, the universities of Tokyo, Osaka and Kyoto as well as the Tokyo Metropolitan Institute of Gerontology. Founded in 1923, the Company currently employs 110 people and is headquartered in the Hongo area of Tokyo, Japan with a logistics center in Katsushima in Tokyo, Japan. Annual turnover for 2003 was 57.5 million USD.


Publisher Contact Information:

The Genetics Company
+41 44 200 2277
breuer@the-genetics.com

Company profile of The Genetics Company
Past press releases of The Genetics Company.

Data


26,152
Tech investments
From our Online Data Service
16,897
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 20€8.0MSecurity
Sep 20€3.0MArtificial Intelligence
Sep 20€55.0MInternet services
Sep 20€1.0MContent management
Sep 19€23.0MKnowledge management
Sep 19€2.3MKnowledge management
Sep 19€15.0MDiagnostics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.